Literature DB >> 19182805

Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.

Aaron D Gitler1, Alessandra Chesi, Melissa L Geddie, Katherine E Strathearn, Shusei Hamamichi, Kathryn J Hill, Kim A Caldwell, Guy A Caldwell, Antony A Cooper, Jean-Christophe Rochet, Susan Lindquist.   

Abstract

Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, collectively referred to as synucleinopathies, are associated with a diverse group of genetic and environmental susceptibilities. The best studied of these is PD. alpha-Synuclein (alpha-syn) has a key role in the pathogenesis of both familial and sporadic PD, but evidence linking it to other predisposition factors is limited. Here we report a strong genetic interaction between alpha-syn and the yeast ortholog of the PD-linked gene ATP13A2 (also known as PARK9). Dopaminergic neuron loss caused by alpha-syn overexpression in animal and neuronal PD models is rescued by coexpression of PARK9. Further, knockdown of the ATP13A2 ortholog in Caenorhabditis elegans enhances alpha-syn misfolding. These data provide a direct functional connection between alpha-syn and another PD susceptibility locus. Manganese exposure is an environmental risk factor linked to PD and PD-like syndromes. We discovered that yeast PARK9 helps to protect cells from manganese toxicity, revealing a connection between PD genetics (alpha-syn and PARK9) and an environmental risk factor (PARK9 and manganese). Finally, we show that additional genes from our yeast screen, with diverse functions, are potent modifiers of alpha-syn-induced neuron loss in animals, establishing a diverse, highly conserved interaction network for alpha-syn.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182805      PMCID: PMC2683786          DOI: 10.1038/ng.300

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  46 in total

1.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  Opposing activities protect against age-onset proteotoxicity.

Authors:  Ehud Cohen; Jan Bieschke; Rhonda M Perciavalle; Jeffery W Kelly; Andrew Dillin
Journal:  Science       Date:  2006-08-10       Impact factor: 47.728

3.  A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study.

Authors:  N Sharma; J Hewett; L J Ozelius; V Ramesh; P J McLean; X O Breakefield; B T Hyman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

5.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.

Authors:  Ira E Clark; Mark W Dodson; Changan Jiang; Joseph H Cao; Jun R Huh; Jae Hong Seol; Soon Ji Yoo; Bruce A Hay; Ming Guo
Journal:  Nature       Date:  2006-05-03       Impact factor: 49.962

6.  A combinatorial code for the interaction of alpha-synuclein with membranes.

Authors:  Shin-ichiro Kubo; Venu M Nemani; Robert J Chalkley; Malcolm D Anthony; Nobutaka Hattori; Yoshikuni Mizuno; Robert H Edwards; Doris L Fortin
Journal:  J Biol Chem       Date:  2005-07-14       Impact factor: 5.157

7.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Authors:  C Lo Bianco; J-L Ridet; B L Schneider; N Deglon; P Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

Review 8.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

9.  DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Authors:  Sara Batelli; Diego Albani; Raffaela Rametta; Letizia Polito; Francesca Prato; Marzia Pesaresi; Alessandro Negro; Gianluigi Forloni
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

10.  Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans.

Authors:  C D Link
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

View more
  246 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.

Authors:  Taiji Tsunemi; Kana Hamada; Dimitri Krainc
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

3.  Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction.

Authors:  Violetta N Pivtoraiko; Adam J Harrington; Burton J Mader; Austin M Luker; Guy A Caldwell; Kim A Caldwell; Kevin A Roth; John J Shacka
Journal:  J Neurochem       Date:  2010-06-01       Impact factor: 5.372

Review 4.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 5.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

6.  Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway.

Authors:  George K Tofaris; Hyoung Tae Kim; Raphael Hourez; Jin-Woo Jung; Kwang Pyo Kim; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-27       Impact factor: 11.205

7.  Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.

Authors:  Benjamin Dehay; Alfredo Ramirez; Marta Martinez-Vicente; Celine Perier; Marie-Hélène Canron; Evelyne Doudnikoff; Anne Vital; Miquel Vila; Christine Klein; Erwan Bezard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

8.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

9.  Manganese accumulates within golgi apparatus in dopaminergic cells as revealed by synchrotron X-ray fluorescence nanoimaging.

Authors:  Asunción Carmona; Guillaume Devès; Stéphane Roudeau; Peter Cloetens; Sylvain Bohic; Richard Ortega
Journal:  ACS Chem Neurosci       Date:  2009-12-17       Impact factor: 4.418

Review 10.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.